Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mitigation of Doxorubicin-Induced Cardiotoxicity by Phytochemicals in Micelles

Award Number: R15CA227754
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2019
PERIOD OF PERFORMANCE END DATE: 05/31/2023

Group Awards By:

View Award Description

Mitigation of Doxorubicin-Induced Cardiotoxicity by Phytochemicals in Micelles - PROJECT SUMMARY/ABSTRACT Doxorubicin (DOX) is a potent chemotherapeutic agent reserved for second line therapy, such as recurrent ovarian cancer, due to its cardiotoxicity and drug resistance issues. With a cumulative lifetime dose limit of 450-550 mg/m2 patients who have benefited from its use before may be barred from further use in any relapses. One promising solution to DOX's cardiotoxicity and chemoresistance is through the use of phytochemicals such as resveratrol (RES), curcumin (CUR), or quercetin (QUE). Although these phytochemicals have been shown to be cardioprotective and can overcome tumor resistance through chemosensitization, they require long pre-treatment times and have short biologic half-lives, restricting their value in addressing DOX's limitations. However, our preliminary in vitro and in vivo research suggests that these phytochemicals, when dosed concurrently in specific combinations in polymeric micelles with existing DOX formulations, are both cardioprotective and chemosensitizing while delivering clinically relevant concentrations of the molecules. The proposed project will extend our preliminary work through two specific aims. Specific Aim 1 will establish preclinical safety and pharmacokinetic profiles for the micellar phytochemicals for use with DOX. Specific Aim 2 will validate the efficacy of the complementary therapeutic approach, i.e., cardioprotection with chemosensitization, in ovarian cancer xenograft mouse models. The significance of the work lies in developing a complementary therapeutic strategy using phytochemicals as a cost-effective strategy to mitigate DOX-induced cardiotoxicity and to chemosensitize resistant cells. By effecting these changes, the cumulative lifetime dose limit of DOX will be increased, making it available for wider applications, including recurrent relapses. Further, these effects will be accomplished without changing the current dosing schedule, increasing the likelihood of patient compliance. The impact of this proposal lies in addressing both mechanisms of DOX-induced cardiotoxicity, ROS and TOPIIβ inhibition, without compromising DOX efficacy or resulting in additional side effects associated with the complementary approach. The global impact of this project lies in addressing the under-utilization of DOX use through a complementary approach, thus increasing the range of treatment options and ultimately the quality of care for patients. In addition, this approach to developing micellar phytochemicals has significant potential for use with other chemotherapeutic agents for which drug resistance is a concern. This R15 application offers excellent research training opportunities for undergraduate, graduate, and pharmacy students and will make significant contributions to the enhancement of the Pacific University research infrastructure while strengthening Oregon State University's biomedical research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$100,532 )
2024	2019	PACIFIC UNIVERSITY	2043 COLLEGE WAY	FOREST GROVE	OR	97116	WASHINGTON	USA	Cancer Treatment Research	000	1	2/1/2024	NEW	-$100,532
														Subtotal = -$100,532

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	PACIFIC UNIVERSITY	2043 COLLEGE WAY	FOREST GROVE	OR	97116	WASHINGTON	USA	Cancer Treatment Research	000	1	6/3/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $396,541 )
2019	2019	PACIFIC UNIVERSITY	2043 COLLEGE WAY	FOREST GROVE	OR	97116	WASHINGTON	USA	Cancer Treatment Research	000	1	5/17/2019	NEW	$396,541
														Subtotal = $396,541

Grand Total All Awards = $296,009

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mitigation of Doxorubicin-Induced Cardiotoxicity by Phytochemicals in Micelles

Award Number: R15CA227754

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2019

PERIOD OF PERFORMANCE END DATE: 05/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer